Stocks · News reference

8-K filing — Aptevo Therapeutics Inc. (APVO)

Jul 27, 2026, 8:05 PMSEC EDGAR

Filed: 2026-07-27 AccNo: 0001193125-26-318056 Size: 184 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 12:32 PMBenzinga Newsdesk
Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of $(151.20) per share
Read original at benzinga
APVO
SEC EDGARAug 14, 2026, 12:10 PMSEC EDGAR
8-K filing — Aptevo Therapeutics Inc. (APVO)
Filed: 2026-08-14 AccNo: 0001193125-26-350537 Size: 210 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
APVO
BenzingaAug 13, 2026, 8:19 PMBenzinga Newsdesk
Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE
Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously
Read original at benzinga
APVO
BenzingaAug 12, 2026, 4:35 PMBenzinga Newsdesk
Aptevo Therapeutics shares are trading lower. The company announced exercise of existing warrants and PIPE for $4.5 million gross proceeds.
Read original at benzinga
APVO